Journal of Clinical Oncology
Articles in this Issue
A novel large language model framework for automated extraction of pathology data in radical cystectomy.
876 Background: Manual chart review has long been the standard for data collection in clinical research; however, this app...
Relapsed/refractory clinically advanced (CA) testicular non-seminomatous germ cell tumors (NSGCT): A genomic landscape study.
618 Background: The successful outcome for most men with NSGCT of testis after surgery and, in some cases, chemotherapy is...
Gaps in BRCA mutation testing among mCRPC patients: Insights from US cancer practices (2018–2024).
102 Background: Treatment of metastatic castration-resistant prostate cancer (mCRPC) has advanced with the approval of pol...
Spatial and molecular determinants of response in penile squamous cell carcinoma.
12 Background: Penile squamous cell carcinoma (PSCC) is a rare, aggressive malignancy with limited treatment options and p...
Baseline and longitudinal body composition profile association with immune-checkpoint inhibitor (ICI) outcomes in metastatic clear-cell renal cell carcinoma (mccRCC).
553 Background: Body composition parameters, including skeletal muscle and fat distribution, have been associated with out...
A phase 2 trial of darolutamide to enhance prostate-specific membrane antigen expression in patients with localized prostate cancer (Daro-PET).
310 Background: PSMA PET/CT improves prostate cancer detection and guides PSMA-targeted therapies. Preclinical data sugges...
Predictive associations between serum oxo-androgens, race, and radiographic progression-free survival (rPFS) among patients treated with apalutamide (Apa), abiraterone acetate (AA) plus prednisone (P) in the PANTHER study.
247 Background: Prior studies have demonstrated that the hormonal environment in which prostate cancer develops may predic...
Pharmacokinetics and dosimetry of lutetium Lu 177 zadavotide guraxetan in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the ECLIPSE sub-study.
174 Background: ECLIPSE (NCT05204927) is an ongoing confirmatory, pivotal, randomized, open-label, multicenter Phase 3 tri...
Comparison of docetaxel triplet therapy with androgen receptor pathway inhibitor (ARPI) doublet in US veterans with metastatic hormone sensitive prostate cancer (mHSPC).
185 Background: Combination therapy has improved survival in clinical trials of mHSPC, but there are no head-to-head studi...
Effects of 3β-HSD1 on back-conversion and androgen signaling in CRPC.
238 Background: Dihydrotestosterone (DHT), the principal androgen driving prostate cancer progression, is synthesized in t...
MEVPRO-3: Phase III trial of mevrometostat plus enzalutamide (versus placebo plus enzalutamide) in metastatic castration-sensitive prostate cancer (mCSPC).
TPS284 Background: Enhancer of zeste homolog 2 (EZH2) enzymatic activity plays a crucial role in prostate cancer progressi...
Predicting cancer organ tropism in mCRPC patients using triple-tracer PET imaging radiomics clustering from the 3TMPO cohort study.
29 Background: The 3TMPO study has characterized the prevalence of intrapatient intermetastatic heterogeneity (IIH) in mCR...
Enfortumab vedotin (EV) related cutaneous toxicity to predict metabolic response on fluorodeoxyglucose (FDG)-positron emission tomography (PET) scan in advanced urothelial carcinoma (aUC): A single-center experience.
736 Background: EV is an antibody–drug conjugate approved for aUC after chemotherapy and immune checkpoint inhibitors. Cut...
Influence of concomitant distant lymph node metastases in metastatic hormone-sensitive prostate cancer patients with bone metastases.
116 Background: Most patients with metastatic hormone-sensitive prostate cancer (mHSPC) are burdened by bone metastases. H...
A randomized phase 2 study of enhanced AR blockade with enzalutamide in high-risk patients with biochemical relapse undergoing salvage radiation: Final results from RTOG 3506 (STEEL).
156 Background: Patients with high-risk features who experience biochemical relapse (BCR) after radical prostatectomy (RP)...
Randomized pilot trial of pre-visit patient education as preparation for decision making in newly diagnosed prostate cancer (PrepDM).
361 Background: Men with newly diagnosed prostate cancer (PCa) face preference-sensitive choices among currently available...
Effects of a diet high in omega-3 polyunsaturated fatty acids (PUFAs) on inhibition of soluble epoxide hydrolase (sEH) and mitigation of painful docetaxel-induced peripheral neuropathy in mice.
140 Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a painful and frequently persistent and debilitating...
High comorbidity as a predictor of poorer survival and ARPI efficacy in metastatic prostate cancer.
72 Background: The prognostic impact of comorbidity burden in metastatic prostate cancer (mPC) remains uncertain. This stu...
Gemcitabine intravesical system (Gem-iDRS) in combination with cetrelimab (CET) versus chemoradiotherapy (CRT) in muscle-invasive bladder cancer (MIBC): SunRISe-2 final results.
635 Background: Bladder sparing is an important therapeutic goal in MIBC. Definitive treatment for localized MIBC is CRT o...
SAVE: A multicenter randomized phase 2 trial of salvage radiotherapy (SRT) with androgen-deprivation therapy (ADT) versus apalutamide (Apa) for biochemical progression after radical prostatectomy (RP).
364 Background: Adding 6 months of ADT to SRT can negatively impact health-related quality of life (HRQoL). SAVE evaluated...
Comparison of quantitative functional RAD51 foci and genomic alterations in predicting PARPi response in mCRPC: A multicenter real-world study.
114 Background: Currently, the clinical outcomes of poly(ADP-ribose) polymerase (PARP) inhibitors varied widely in metasta...
Trends in PSA and metastatic prostate cancer at presentation in the United States from 2004-2022.
76 Background: The introduction of prostate-specific antigen (PSA) screening in the mid-1980s led to an increase in the di...
Palliative care utilization and hospitalization outcomes among patients with renal cell carcinoma: A 2020-2022 National Inpatient Sample analysis.
432 Background: Renal cell carcinoma (RCC) is an aggressive malignancy with significant symptom burden. Advances in target...
Real-world determinants of testosterone recovery following androgen deprivation therapy in patients with localized prostate cancer.
353 Background: Androgen deprivation therapy (ADT) is a cornerstone of localized prostate cancer management, yet testoster...
Efficacy and safety of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma and venous tumor thrombus: Results from the first analysis of the PELET trial.
509 Background: Venous tumor thrombus (VTT) in patients with renal cell carcinoma (RCC) represents an aggressive disease f...